| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Hans-Jürgen Möller | Q1577771 |
| P2860 | cites work | Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia | Q21260279 |
| Randomisation to protect against selection bias in healthcare trials | Q24245576 | ||
| A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia | Q24794849 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Framework for design and evaluation of complex interventions to improve health | Q29619503 | ||
| Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. | Q33385675 | ||
| STAR*D: what have we learned? | Q79700849 | ||
| Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany | Q80189015 | ||
| Subjective effects of antipsychotic treatment | Q81311714 | ||
| Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study | Q82108257 | ||
| Rating depressed patients: observer- vs self-assessment | Q33958639 | ||
| Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports | Q34187358 | ||
| Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy | Q34264600 | ||
| Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design | Q34310720 | ||
| Subjective well-being and quality of life under atypical antipsychotic treatment | Q34728089 | ||
| World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia | Q34744755 | ||
| Placebo-controlled studies in depression: necessary, ethical and feasible | Q35094257 | ||
| Research designs for studies evaluating the effectiveness of change and improvement strategies | Q35525558 | ||
| New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off? | Q35805896 | ||
| Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life | Q35906816 | ||
| Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. | Q36007894 | ||
| Switching antipsychotics: an updated review with a focus on quetiapine | Q36276541 | ||
| Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. | Q36504081 | ||
| Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. | Q36890568 | ||
| Do effectiveness ("real world") studies on antipsychotics tell us the real truth? | Q37214661 | ||
| Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales | Q37229333 | ||
| Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach | Q37539807 | ||
| Principle standards and problems regarding proof of efficacy in clinical psychopharmacology | Q37627217 | ||
| The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. | Q38403241 | ||
| Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. | Q40459628 | ||
| Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial | Q44091924 | ||
| The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment | Q44311423 | ||
| Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations | Q44451644 | ||
| Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial | Q44674061 | ||
| Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol | Q44850771 | ||
| Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia | Q45334503 | ||
| Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. | Q45932131 | ||
| Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. | Q46327840 | ||
| Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression | Q47760837 | ||
| Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials | Q49055228 | ||
| Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. | Q50652421 | ||
| Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. | Q51909443 | ||
| Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. | Q51950878 | ||
| Interpreting the efficacy findings in the CATIE study: what clinicians should know. | Q53006399 | ||
| Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. | Q53017376 | ||
| Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". | Q53515140 | ||
| Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. | Q53597276 | ||
| [Are placebo controlled studies on the proof of effectiveness of antidepressants necessary?]. | Q54483394 | ||
| Addressing the limitations of the CATIE study | Q57738653 | ||
| Selection Bias in Clinical Trials With Antipsychotics | Q57847856 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 2 | |
| P921 | main subject | evidence-based medicine | Q691640 |
| medical research | Q2752427 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 199-207 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Dialogues in Clinical Neuroscience | Q24255736 |
| P1476 | title | Effectiveness studies: advantages and disadvantages | |
| P478 | volume | 13 |
| Q58604419 | A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit |
| Q47169473 | A non-randomised pragmatic trial of a school-based group cognitive-behavioural programme for preventing depression in girls |
| Q94581257 | Does It work in Clinical Practice? A Comparison of Colonoscopy Cleansing Effectiveness in Clinical Practice Versus Efficacy from Selected Prospective Trials |
| Q91736800 | Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial |
| Q47746024 | Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study |
| Q64110929 | Manual therapy for chronic migraine: a pragmatic randomised controlled trial study protocol |
| Q47551032 | The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia |
| Q42747344 | The importance of collecting structured clinical information on multiple sclerosis |
| Q47663915 | What can comparative effectiveness research, propensity score and registry study bring to Chinese medicine? |
Search more.